Dr. Reddy's Laboratories Limited (NSE:DRREDDY)
India · Delayed Price · Currency is INR 1,310.90
+81.40 (6.62%)
Oct 26, 2026, 3:28 PM IST
Dr. Reddy's Laboratories Stock Forecast
Stock Price Forecast
According to 37 analysts polled by S&P Global, Dr. Reddy's Laboratories stock has a consensus rating of "Buy" and an average price target of ₹1,351. The average 1-year stock price forecast is 3.06% higher than the current stock price, while the lowest is ₹1,039 (-20.74%) and the highest is ₹1,730 (+31.97%).
Price Target: ₹1,351 (+3.06%)
Analyst Consensus: Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Dr. Reddy's Laboratories stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | May '26 | Jun '26 | Jul '26 | Aug '26 | Sep '26 | Oct '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 12 | 12 | 11 | 11 | 13 | 16 |
| Buy | 5 | 5 | 4 | 4 | 3 | 5 |
| Hold | 10 | 10 | 11 | 11 | 10 | 7 |
| Sell | 6 | 6 | 8 | 8 | 8 | 6 |
| Strong Sell | 6 | 6 | 6 | 5 | 4 | 3 |
| Total | 39 | 39 | 40 | 39 | 38 | 37 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Jefferies | Jefferies | Hold Upgrades ₹1,320 | Hold | Upgrades | ₹1,320 | +0.69% | Oct 26, 2026 |
| J.P. Morgan | J.P. Morgan | Hold Upgrades ₹1,100 → ₹1,270 | Hold | Upgrades | ₹1,100 → ₹1,270 | -3.12% | Oct 25, 2026 |
| Citi | Citi | Buy Upgrades ₹1,040 → ₹1,450 | Buy | Upgrades | ₹1,040 → ₹1,450 | +10.61% | Sep 29, 2026 |
Financial Forecast
Revenue This Year
351.06B
from 335.93B
Increased by 4.50%
Revenue Next Year
393.41B
from 351.06B
Increased by 12.06%
EPS This Year
44.49
from 55.39
Decreased by -19.69%
EPS Next Year
59.08
from 44.49
Increased by 32.81%
EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is INR.